CYP7A1 and metabolic dysfunction-associated steatotic liver disease: Previous studies reported reduced hepatic cholesterol 7-a-monooxygenase (Cyp7a1) and increased ileal Fgf15 mRNA expression in NAFLD model mice (6, 15).